Clinical trials: Atopy
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Asthma, Allergic Rhinitis
Influence of Probiotics on Atopy With Focus on Respiratory Allergic Diseases- Follow-up to 7 Years
The investigators had conducted an initial double-blind, placebo-controlled clinical trial (NCT00318695) to study the effects of probiotic supplementation from birth to 6 months of age in the incidence of atopic diseases at 2…
- Trial name
- NCT00826189
- Where
- Singapore
- Volunteers
- 253 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Atopic Dermatitis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03245385
- Testing
- Treatment with Halobetasol propionate 0.05% topical spray
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Atopic Dermatitis, Eczema Herpeticum
Registry for the Atopic Dermatitis Research Network
The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant database for future studies.
- Trial name
- NCT01494142
- Where
- 9 sites in United States
- Volunteers
- 3,387 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Atopic Dermatitis (AD)
Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis
This study will assess the safety and efficacy of Roflumilast cream versus vehicle applied once a day for 4 weeks by subjects with atopic dermatitis.
- Trial name
- NCT06631170
- Testing
- Roflumilast Cream 0.15%, Vehicle cream
- Where
- 61 sites in China
- Volunteers
- 354 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy
Preventive Medicine Study of Childhood Atopic Diseases
Under environmental intervention programs, to explore the associations between Environmental Tobacco Smoke (ETS) and changes of pulmonary function, cytokines and new-onset asthma between different groups.
- Trial name
- NCT00960596
- Testing
- Health promotion and health education for smoking habits
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Atopic Dermatitis
Pediatric Atopic Dermatitis (AD) Internet Survey
The purpose of this study is to evaluate whether participation in an Internet-based intervention helps improve atopic dermatitis treatment outcomes.
- Trial name
- NCT01385527
- Testing
- Weekly Internet survey, Topical Triamcinolone
- Sponsor
- Wake Forest University
Asthma
A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)
This was a multicenter, parallel-group, double-blind, randomized, placebo-controlled study that enrolled 333 subjects. These subjects were 12-75 years old with atopic asthma, had elevated serum total Immunoglobulin E (IgE), had a…
- Trial name
- EXACT (NCT00096954)
- Testing
- omalizumab (Xolair)
- Volunteers
- 333 people
- Sponsor
- Genentech, Inc.
Moderate-to-severe Atopic Dermatitis
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
Primary Objective: Part A To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score To determine the entry criterion…
- Trial name
- NEURADAD (NCT05203380)
- Testing
- dupilumab
- Where
- 10 sites in United States
- Volunteers
- 45 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis Eczema
Study in Subjects With Moderate Atopic Dermatitis
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in…
- Trial name
- NCT03859986
- Testing
- ALX-101 Gel Vehicle, ALX-101 Gel 5%
- Where
- 22 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Ralexar Therapeutics, Inc.
Atopic Dermatitis (AD)
Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese…
- Trial name
- NCT05959083
- Where
- 18 sites in China
- Volunteers
- 200 people
- Sponsor
- AbbVie
Atopic Dermatitis
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
The main purpose of the study is to assess the long-term tolerability and effectiveness of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADlong (NCT05916365)
- Testing
- Lebrikizumab
- Where
- 32 sites in Germany, Poland
- Volunteers
- 174 people
- Sponsor
- Almirall, S.A.
Dermatitis, Atopic
Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study.
- Trial name
- JADE EXTEND (NCT03422822)
- Testing
- Abrocitinib 100 mg, Abrocitinib 200 mg
- Where
- 539 sites in United States, Argentina and 26 more
- Volunteers
- 3,166 people
- Sponsor
- Pfizer
Asthma
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic…
- Trial name
- NCT00160563
- Testing
- LEVOCETIRIZINE
- Where
- 51 sites in Australia, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- UCB Pharma
Infantile Colics, Constipation
Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete
This is a randomized, single-blind, placebo-controlled study to evaluate the efficacy of the dietary supplement BioAmicus Complete (oral drops; a mixture of 10 strains of lacto- and bifidobacteria) in managing functional…
- Conditions
- Infantile Colics, Constipation, Infantile Diarrhea, Atopic Dermatitis
- Trial name
- NCT07444008
- Testing
- BioAmicus Complete
- Where
- Russia
- Volunteers
- 140 people
- Sponsor
- NovoNatum Ltd
Atopic Dermatitis
Study of OPA-15406 Ointment in Patients With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.
- Trial name
- NCT02914548
- Testing
- OPA-15406
- Where
- 3 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Atopic Diseases
Prevention of Allergic Diseases in Infants
A multi-center, prospective, randomized, controlled, doubleblind intervention clinical Trial is performed to proof the efficiency of hydrolyzed infant formula showing a risk reduction of developing an allergy.
- Trial name
- NCT03489733
- Testing
- Hydrolyzed Formula, Control formula
- Where
- 14 sites in Bulgaria, Czechia and 8 more
- Volunteers
- 1,226 people, healthy volunteers welcome
- Sponsor
- HiPP GmbH & Co. Vertrieb KG
Dermatitis, Atopic
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis
To assess the efficacy of Locobase REPAIR® when used in children with moderate to severe AD
- Trial name
- NCT00673725
- Testing
- Locobase® REPAIR
- Where
- 3 sites in United Kingdom
- Volunteers
- 49 people
- Sponsor
- Astellas Pharma Europe B.V.
Atopic Dermatitis
The Efficacy of Patients With Moderate to Severe Atopic Dermatitis Treated With Chinese Herbal Medicine
Conduct a clinical trial of integration of Chinese and Western medicine to evaluate whether the association of traditional Chinese medicine therapy has a remission effect on atopic dermatitis, and to explore the remission of…
- Trial name
- NCT04686955
- Testing
- Xiao-Xian-Gui-Fu-Tang
- Where
- 2 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Atopic Dermatitis, Eczema, Atopic
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
The goal of this clinical trial is to compare a step-down strategy of spacing dupilumab injections with a standard maintenance treatment in adolescents and adults with controlled Atopic dermatitis (AD) for at least six months.
- Trial name
- MADULO (NCT05642208)
- Testing
- Dupilumab step-down
- Where
- 32 sites in France, Reunion
- Volunteers
- 256 people
- Sponsor
- Nantes University Hospital